Background and Objectives The clinical outcomes of zotarolimus-eluting stent(ZES, Endeavor Resolute) for long coronary lesions are not clear yet, although sirolimus-eluting stent(SES, Cypher) showed favorable effects for such lesions. We compared the clinical outcomes of these two drug-eluting stents for long coronary lesions.Subjects and Methods We analyzed the medical and angiographic records of 304 lesions in 261 patients who were treated with ZES and 290 lesions in 259 patients who were treated with SES for long coronary lesions(stent length ��� 30mm). Each patient was treated with same kind of stent, if they need multiple stents implantation for one lesion or multiple vessels. Clinical outcomes of ZES group and SES group were compared.Results Baseline and procedural characteristics of the two groups were similar. However, more patients in ZES group underwent stent implantation due to acute myocardial infarction(MI) than SES group(28.6% vs. 21.4%, p=0.042) and more patients in SES group underwent multi-vessel stent implantation than ZES group(35.9% vs. 45.5%, p=0.017). Follow-up coronary angiography was done in 56.6% of ZES group and 56.9% of SES group(p=0.938). The rates of 2-year major adverse cardiac event, a composite of MI, cardiac death and target vessel revascularization, were similar between the two groups(5.6% vs. 7.2%, p=0.862). However, the incidence of 2-year stent thrombosis was significantly lower in ZES group(0.0% vs. 1.7%, p= 0.042).Conclusion ZES showed non-inferior clinical outcomes for long coronary lesions when compared to SES. Furthermore, the incidence of 2-year stent thrombosis was significantly lower in ZES group.